or more of the various forms of NO or CO.

22. A method of augmenting the actions of cAMP in one or more effector systems while reducing cAMP action in a nociceptive system in an anatomical site where nociceptive tissue is in close proximity to one or more effector systems comprising application of one or more agents that augment or potentiate the effects of cyclic nucleotides by modulating the activities of cyclic nucleotide phosphodiesterases.

23. A method of augmenting the actions of cAMP in one or more effector systems while reducing cAMP action in a nociceptive system in an anatomical site where nociceptive tissue is in close proximity to one or more effector systems comprising application of one or more agents which potentiates or augments the action of cAMP in said effector systems and, in said nociceptive system, causes an increase of cGMP relative to cAMP, so that there is an overall reduction in cAMP but with relatively more cGMP.

24. A method as claimed in Claim 22 wherein alteration of the said actions of cAMP is caused by application of an agent which inhibits phosphodiesterase in smooth muscle and activates cAMP phosphodiesterase in nervous tissue.

25. A method as claimed in Claim 20 wherein said anatomical site is engorgeable genital tissue.

26. A method as claimed in Claim 25 wherein said anatomical site is the penis or the clitoris.

27. A method as claimed in Claim 21 wherein said anatomical site is engorgeable genital tissue.

28. A method as claimed in Claim 27 wherein said anatomical site is the penis or the clitoris.

29. A method as claimed in Claim 22 wherein said anatomical site is engorgeable genital tissue.

30. A method as claimed in Claim 29 wherein said anatomical site is the penis or the clitoris.

31. A method as claimed in Claim 23 wherein said anatomical site is engorgeable genital tissue.

32. A method as claimed in Claim 31 wherein said anatomical site is the penis or the clitoris.

33. A method as claimed in Claim 24 wherein said anatomical site is engorgeable genital tissue.

34. A method as claimed in Claim 33 wherein said anatomical site is the penis or the clitoris.

35. A method for enhancing penile or clitoral erection comprising the use of one or more agents in an effective amount that can augment the effect of cAMP as well as augment the effect of cGMP with minimal or no pain.

36. A method as claimed in claim 35 wherein said one or more agents can augment the effect of cAMP in smooth muscle as well as augment the effect of cGMP in nervous tissue.

37. A method as claimed in Claim 35 wherein said one or more agents augments the effect of cAMP by stimulating adenylyl cyclase and/or inhibiting cyclic nucleotide phosphodiesterase activity in smooth muscle while augmenting the effect of cGMP in nervous tissue.

38. A method as claimed in Claim 35 wherein said one or more agents augments the effect of cGMP and inhibits cyclic nucleotide phosphodiesterase by generating nitric oxide.

39. A method as claimed in Claim 37 wherein the cyclic nucleotide phosphodiesterase is PDE3.

40. A method as claimed in Claim 38 wherein said one or more agents is selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine, molsidomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, N-hydroxy-L-arginine, S,S-dinitrosodithiol, and NO gas.

41. A method as claimed in Claim 20 whereby said one or more agents is delivered by any route that will affect smooth muscle and nerves in engorgeable genital tissue.

42. A method as claimed in Claim 21 whereby said one or more agents is delivered by any route that will affect smooth muscle and nerves in engorgeable genital tissue.

43. A method as claimed in Claim 22 whereby said one or more agents is delivered by any route that will affect smooth muscle and nerves in engorgeable genital tissue.

44. A method as claimed in Claim 23 whereby said one or more agents is delivered by any route that will affect smooth muscle and nerves in engorgeable genital tissue.

45. A method as claimed in Claim 35 whereby said one or more agents is delivered by any route that will affect smooth muscle and nerves in engorgeable genital tissue.

46. A method as claimed in Claim 35 wherein two agents are used and the agent that can

augment the effect of cGMP does so by generating NO or CO.

47. A method as claimed in Claim 35 wherein two agents are used, one of said agents augments the effect of cAMP by stimulating adenylyl cyclase in smooth muscle and the second of said agents inhibits cyclic nucleotide phosphodiesterase in smooth muscle.

48. A method as claimed in Claim 47 wherein said cyclic nucleotide phosphodiesterase is PDE3.

49. A method as claimed in Claim 46 wherein said agent which generates NO is selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine, molsidomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, N-hydroxy-L-arginine, S,S-dinitrosodithiol and NO gas.

50. A method as claimed in Claim 35 wherein the agent that augments or potentiates the effect of cAMP is selected from the group consisting of PGE1, VIP, forskolin, acetylcholine, and calcitonin gene related peptide.

51. A method as claimed in Claim 35 whereby said one or more agents are delivered by any route that will affect penile or clitoral smooth muscle and nerves.

52. In an anatomical site where nociceptive tissue is in close proximity to one or more effector systems, a method for enhancing said effector system while reducing nociception in said nociceptive tissue comprising application of an agent or agents that potentiate or augment the action of cAMP in said effector systems and in said nociceptive tissue cause an increase of cGMP relative to cAMP.